Read More

Aileron Therapeutics Announces Acquisition Of Lung Therapeutics; Financing Proceeds Of ~$18M From A Private Placement Anticipated To Fund Completion Of The Ongoing Phase 1b Clinical Study Of LTI-03 In IPF And For General Corporate Purposes

Acquisition includes multiple clinical stage, orphan pulmonary disease candidates, including LTI-03, a Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis (IPF)Financing

ALRN